Clinical trial
Scleroderma Lung Disease
NCT00004563 · The University of Texas Health Science Center, Houston, Other · Completed
Key facts
| NCT number | NCT00004563 |
|---|---|
| Title | Scleroderma Lung Disease |
| Official title | Cyclophosphamide Versus Placebo in Scleroderma Lung Study |
| Acronym | SLS |
| Lead sponsor | The University of Texas Health Science Center, Houston, Other |
| Collaborators | National Heart, Lung, and Blood Institute (NHLBI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lung Diseases, Pulmonary Fibrosis, Systemic Scleroderma, Scleroderma, Systemic |
| Intervention type | Drug |
| Interventions | Cyclophosphamide, Placebo |
| Enrollment | 158 |
| Start date | Aug 1, 1999 |
| Primary completion | May 1, 2013 |
| Completion | May 1, 2013 |
| First posted | Feb 10, 2000 |
| Last update posted | Mar 27, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: